http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 02:43:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html <div class="xn-content"> <p><b>New approvals for Leqembi</b>^®<b> and additional strategic partnerships</b></p><p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- </p> <p><b>Events during the second quarter 2026</b></p><ul type="disc"><li>Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (<chron>April 2026</chron> to <chron>March 2027</chron>) of a total of <money>JPY 143.5 billion</money> (approximately <money>SEK 8.4 billion</money>), corresponding to 63% growth compared with the previous year</li><li>BioArctic entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly targeting neurodegeneration. As part of the agreement, BioArctic will http://www.streetinsider.com/Press+Releases/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html Wed, 26 Aug 2026 02:43:00 -0400 A.06822034 BIOA-B BIOA-B.ST O.20026344 http://www.streetinsider.com/Press+Releases/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html <div class="xn-content"> <p><b>New approvals for Leqembi</b>^®<b> and additional strategic partnerships</b></p><p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- </p> <p><b>Events during the second quarter 2026</b></p><ul type="disc"><li>Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (<chron>April 2026</chron> to <chron>March 2027</chron>) of a total of <money>JPY 143.5 billion</money> (approximately <money>SEK 8.4 billion</money>), corresponding to 63% growth compared with the previous year</li><li>BioArctic entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly targeting neurodegeneration. As part of the agreement, BioArctic will http://www.streetinsider.com/Press+Releases/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html Wed, 26 Aug 2026 02:43:00 -0400 A.06822034 BIOA-B BIOA-B.ST O.20026344 http://www.streetinsider.com/Press+Releases/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html <div class="xn-content"> <p><b>New approvals for Leqembi</b>^®<b> and additional strategic partnerships</b></p><p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- </p> <p><b>Events during the second quarter 2026</b></p><ul type="disc"><li>Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (<chron>April 2026</chron> to <chron>March 2027</chron>) of a total of <money>JPY 143.5 billion</money> (approximately <money>SEK 8.4 billion</money>), corresponding to 63% growth compared with the previous year</li><li>BioArctic entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly targeting neurodegeneration. As part of the agreement, BioArctic will http://www.streetinsider.com/Press+Releases/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html Wed, 26 Aug 2026 02:43:00 -0400 A.06822034 BIOA-B BIOA-B.ST O.20026344 http://www.streetinsider.com/Press+Releases/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html <div class="xn-content"> <p><b>New approvals for Leqembi</b>^®<b> and additional strategic partnerships</b></p><p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- </p> <p><b>Events during the second quarter 2026</b></p><ul type="disc"><li>Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (<chron>April 2026</chron> to <chron>March 2027</chron>) of a total of <money>JPY 143.5 billion</money> (approximately <money>SEK 8.4 billion</money>), corresponding to 63% growth compared with the previous year</li><li>BioArctic entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly targeting neurodegeneration. As part of the agreement, BioArctic will http://www.streetinsider.com/Press+Releases/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html Wed, 26 Aug 2026 02:43:00 -0400 A.06822034 BIOA-B BIOA-B.ST O.20026344 http://www.streetinsider.com/PRNewswire/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html <div class="xn-content"> <p><b>New approvals for Leqembi</b>^®<b> and additional strategic partnerships</b></p><p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- </p> <p><b>Events during the second quarter 2026</b></p><ul type="disc"><li>Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (<chron>April 2026</chron> to <chron>March 2027</chron>) of a total of <money>JPY 143.5 billion</money> (approximately <money>SEK 8.4 billion</money>), corresponding to 63% growth compared with the previous year</li><li>BioArctic entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly targeting neurodegeneration. As part of the agreement, BioArctic will http://www.streetinsider.com/PRNewswire/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html Wed, 26 Aug 2026 02:43:00 -0400 A.06822034 BIOA-B BIOA-B.ST O.20026344 http://www.streetinsider.com/PRNewswire/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html <div class="xn-content"> <p><b>New approvals for Leqembi</b>^®<b> and additional strategic partnerships</b></p><p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- </p> <p><b>Events during the second quarter 2026</b></p><ul type="disc"><li>Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (<chron>April 2026</chron> to <chron>March 2027</chron>) of a total of <money>JPY 143.5 billion</money> (approximately <money>SEK 8.4 billion</money>), corresponding to 63% growth compared with the previous year</li><li>BioArctic entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly targeting neurodegeneration. As part of the agreement, BioArctic will http://www.streetinsider.com/PRNewswire/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html Wed, 26 Aug 2026 02:43:00 -0400 A.06822034 BIOA-B BIOA-B.ST O.20026344 http://www.streetinsider.com/PRNewswire/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html <div class="xn-content"> <p><b>New approvals for Leqembi</b>^®<b> and additional strategic partnerships</b></p><p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- </p> <p><b>Events during the second quarter 2026</b></p><ul type="disc"><li>Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (<chron>April 2026</chron> to <chron>March 2027</chron>) of a total of <money>JPY 143.5 billion</money> (approximately <money>SEK 8.4 billion</money>), corresponding to 63% growth compared with the previous year</li><li>BioArctic entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly targeting neurodegeneration. As part of the agreement, BioArctic will http://www.streetinsider.com/PRNewswire/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html Wed, 26 Aug 2026 02:43:00 -0400 A.06822034 BIOA-B BIOA-B.ST O.20026344 http://www.streetinsider.com/PRNewswire/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html <div class="xn-content"> <p><b>New approvals for Leqembi</b>^®<b> and additional strategic partnerships</b></p><p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- </p> <p><b>Events during the second quarter 2026</b></p><ul type="disc"><li>Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (<chron>April 2026</chron> to <chron>March 2027</chron>) of a total of <money>JPY 143.5 billion</money> (approximately <money>SEK 8.4 billion</money>), corresponding to 63% growth compared with the previous year</li><li>BioArctic entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly targeting neurodegeneration. As part of the agreement, BioArctic will http://www.streetinsider.com/PRNewswire/BioArctic%3A+Interim+Report+for+the+period+April+-+June+2026/26976349.html Wed, 26 Aug 2026 02:43:00 -0400 A.06822034 BIOA-B BIOA-B.ST O.20026344 http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/Press+Releases/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593 http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>July 29, 2026</chron></span> /PRNewswire/ -- <b>BioArctic AB's (publ) </b>(NASDAQ STOCKHOLM: BIOA B)<b> partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of <money>JPY 29.3 billion</money> were recorded in the period. This results in a royalty to BioArctic amounting to <money>SEK 179 million</money>, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025. </b></p> <p>The results in Q2 2025 included a one-time stockpiling effect in the Chinese market http://www.streetinsider.com/PRNewswire/Sales+of+Leqembi%C2%AE+totaled+29.3+billion+yen+in+the+second+quarter+2026/26829931.html Wed, 29 Jul 2026 06:27:00 -0400 A.19655944 A.50216934 B BIOA BIOA-B BIOA-B.ST O.03307993 O.20026294 O.34376593